Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
2007-01-30
2007-01-30
Padmanabhan, Sreeni (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
C514S728000, C514S729000, C514S731000, C514S739000, C514S772000, C514S783000, C514S937000, C514S938000, C514S975000
Reexamination Certificate
active
10010914
ABSTRACT:
A pharmaceutical composition for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent capable of dispersing or solubilizing the retinide. The solvent comprises an alcohol, such as ethanol, in combination with an alkoxylated castor oil, such as CREMOPHOR® EL, or comprising a retinide, such as fenretinide, in an emulsion composed of a lipoid dispersed in an aqueous phase, a stabilizing amount of a non-ionic surfactant, optionally a solvent, and optionally an isotonic agent. In addition, a method of use in the treatment of hyperproliferative disorders, such as cancers is described.
REFERENCES:
patent: 4190594 (1980-02-01), Gander et al.
patent: 4323581 (1982-04-01), Gander
patent: 4665098 (1987-05-01), Gibbs et al.
patent: 4960799 (1990-10-01), Nagy
patent: 5464870 (1995-11-01), Veronesi et al.
patent: 5504102 (1996-04-01), Agharkar et al.
patent: 5599953 (1997-02-01), Curley, Jr. et al.
patent: 5663377 (1997-09-01), Curley, Jr. et al.
patent: 5767146 (1998-06-01), Shudo et al.
patent: 5827522 (1998-10-01), Nowak
patent: 5925776 (1999-07-01), Nikolayev et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 6660286 (2003-12-01), Lambert et al.
patent: 2002/0143062 (2002-10-01), Lopez-Berestein et al.
patent: WO 98/57630 (1998-12-01), None
patent: WO00/00207 (2000-01-01), None
patent: WO 00/00207 (2000-01-01), None
Product data sheet, TAXOL®, MeadJohnson Oncology Products (Jul. 2000).
Product data sheet, Sandimmune®, Novartis (Nov. 1999).
Technical Leaflet, Cremophor® EL, BASF (Jul. 1997).
Product data sheet, Cremophor® EL, BASF (Jul. 1999).
International Search Report for International Application Serial No. PCT/US01/46548 dated May 31, 2002.
Grit et al., “Chemical Stability of Liposomes: Implications for their Physical Stability,”Chemistry and Physics of Lipids, 64, pp. 3-18 (1993).
Young et al., “Phospholid-Stabilized Nanoparticles of Cyclosporine A by Rapid Expansion from Supercritical to Aqueous Solution,”AAPS PharmSciTech 2003; 5(1) Article 11 (http://www.aapspharmscitech.org).
“Product Development of Fenretinide, NSC 374551, Intravenous Formulation” European Journal of Cancer, Pergamon Press, Oxford, GB. vol. 38, p. S21 (Nov. 2002).
Supplementary European Search Report for European Patent Application No. 01 98 9170 mailed on Apr. 6, 2006.
Gupta Shanker
Maurer Barry J.
Reynolds C. Patrick
Vishnuvajjala B. Rao
Children's Hospital Los Angeles
Choi Frank
Myers Bigel Sibley & Sajovec P.A.
Padmanabhan Sreeni
LandOfFree
Pharmaceutical compositions of fenretinide having increased... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions of fenretinide having increased..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of fenretinide having increased... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3764687